Semaglutide "cuts dementia risk", say the headlines. The number is modelled, and the real trial already failed
A new analysis of the SELECT trial reports a lower predicted dementia risk on semaglutide. But it measured a blood-protein signature, not actual dementia — and the drug's dedicated Alzheimer's trials found no clinical benefit last November.
